ERBB2 and breast carcinoma: Uncovering the miRNA layer of genetic regulation will be part of the optimal approach to targeted therapy in breast cancer; this involves improving our understanding of molecular targets such as ER, PR and HER2/neu in addition to identifying novel molecular pathways and targets in order to predict response and to identify pathways of primary and acquired resistance to therapy.